DK200800075A - Krystallinsk base af escitalopram og orodispergerbare tabletter indeholdende escitaloprambase - Google Patents
Krystallinsk base af escitalopram og orodispergerbare tabletter indeholdende escitaloprambase Download PDFInfo
- Publication number
- DK200800075A DK200800075A DK200800075A DKPA200800075A DK200800075A DK 200800075 A DK200800075 A DK 200800075A DK 200800075 A DK200800075 A DK 200800075A DK PA200800075 A DKPA200800075 A DK PA200800075A DK 200800075 A DK200800075 A DK 200800075A
- Authority
- DK
- Denmark
- Prior art keywords
- escitalopram
- free base
- salt
- crystalline
- base
- Prior art date
Links
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 title claims 37
- 229960004341 escitalopram Drugs 0.000 title claims 36
- 238000000034 method Methods 0.000 claims 18
- 239000012458 free base Substances 0.000 claims 15
- 238000002844 melting Methods 0.000 claims 11
- 230000008018 melting Effects 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 9
- 239000008186 active pharmaceutical agent Substances 0.000 claims 7
- 239000000945 filler Substances 0.000 claims 7
- 239000012535 impurity Substances 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 239000002585 base Substances 0.000 claims 5
- WIHMBLDNRMIGDW-BDQAORGHSA-N escitalopram hydrobromide Chemical compound Br.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WIHMBLDNRMIGDW-BDQAORGHSA-N 0.000 claims 5
- 150000003891 oxalate salts Chemical class 0.000 claims 5
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims 2
- 229960005086 escitalopram oxalate Drugs 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 239000005426 pharmaceutical component Substances 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 229960004587 carisoprodol Drugs 0.000 claims 1
- OFZCIYFFPZCNJE-UHFFFAOYSA-N carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 229960002563 disulfiram Drugs 0.000 claims 1
- 229960002767 ethosuximide Drugs 0.000 claims 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims 1
- 229960002297 fenofibrate Drugs 0.000 claims 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229960002146 guaifenesin Drugs 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229960002247 lomustine Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 150000002772 monosaccharides Chemical group 0.000 claims 1
- 229960000762 perphenazine Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 238000003825 pressing Methods 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 229960004453 trimethadione Drugs 0.000 claims 1
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Claims (34)
1. Escitalopram fri base i fast form.
2. Escitalopram fri base ifølge krav 1,kendetegnet ved, at den omfatter krystallinsk escitalopram.
3. Escitalopram fri base ifølge krav 2, kendetegnet ved, at den er mindst 90 % krystallinsk, navnlig mindst 95 % krystallinsk og nærmere bestemt mindst 98. krystallinsk.
4. Escitalopram fri base ifølge krav 1, kendetegnet ved, at den er krystallinsk.
5. Farmaceutisk sammensætning, der indeholder escitalopram fri base ifølge kravene 1 til 4.
6. Fremgangsmåde til fremstilling af escitalopram fri base eller et salt deraf, kendetegnet ved, at escitalopramhydrobromid udfældes i krystallinsk form fra et opløsningsmiddel og separeres fra opløsningsmidlet, eventuelt omkrystalliseres én eller flere gange og derefter omdannes til escitalopram fri base eller et salt deraf, forudsat, at det fremstillede escitalopram-salt ikke er hydrobromidet.
7. Fremgangsmåde ifølge krav 6 til fremstilling af escitalopram fri base eller et salt deraf, kendetegnet ved, at escitalopramhydrobromidet udfældes fra et råt escitalopram.
8. Fremgangsmåde ifølge krav 6 eller 7 til fremstilling af escitalopram fri base eller et salt deraf, kendetegnet ved, at én eller flere urenheder med formlerne (II) eller (III)
hvor Z er halogen, cyano eller -CONHz, R1 og R2 uafhængigt er hydrogen eller methyl, forudsat, at hvis både R1 og R2 er methyl, så kan Z ikke være cyano, og bindingen, som er tegnet som en siksaklinje i formlen (III), angiver, at konfigurationen omkring dobbeltbindingen kan være E- eller Z-; fjernes fra eller reduceres i escitalopramet ved fremgangsmåden.
9. Fremgangsmåde ifølge krav 8, hvor urenhederne har formlen (II), hvor Z er brom eller chlor, og R1 og R2 begge er methyl, Z er -CONH2, og R1 og R2 begge er methyl, eller Z er cyano, R1 er hydrogen, og R2 er methyl; eller med formlen (III), hvor konfigurationen omkring dobbeltbindingen erZ.
10. Fremgangsmåde ifølge et hvilket som helst af kravene 7 til 9, hvor det rå escitalopram underkastes en indledende oprensning, før escitalopramhydrobromidet udfældes i krystallinsk form.
11. Fremgangsmåde ifølge et hvilket som helst af kravene 6 til 10, kendetegnet ved, at escitalopramhydrobromidet omdannes til escitalopram fri base eller escitalopram-oxalat.
12. Krystallinsk base af escitalopram eller et oxalatsalt af escitalopram, kendetegnet ved, at den(det) indeholder mindre end 0,20% urenheder bortset fra R-citalopram, navnlig mindre end 0,10 %.
13. Krystallinsk base eller oxalatsalt ifølge krav 12, kendetegnet ved, at den(det) indeholder mindre end 0,10% af en hvilken som helst særskilt urenhed bortset fra R-citalopram.
14. Krystallinsk base af escitalopram eller et oxalatsalt af escitalopram fremstillet ved fremgangsmåden ifølge et hvilket som helst af kravene 6-11.
15. Base eller oxalatsalt ifølge krav 14, kendetegnet ved, at den(det) indeholder mindre end 0,20 % urenheder bortset fra R-citalopram, navnlig mindre end 0,10 %.
16. Krystallinsk base eller oxalatsalt ifølge krav 15, kendetegnet ved, at den(det) indeholder mindre end 0,10 % af en hvilken som helst særskilt urenhed bortset fra R-citalopram.
17. Fremgangsmåde til fremstilling af et salt af escitalopram, kendetegnet ved, at escitalopram fri base udfældes i fast form fra et opløsningsmiddel og separeres fra opløsningsmidlet, eventuelt omkrystalliseres én eller flere gange og derefter omdannes til et salt af escitalopram.
18. Fremgangsmåde ifølge krav 17 til fremstilling af et salt af escitalopram, kendetegnet ved, at escitalopram fri base udfældes fra et råt escitalopram.
20. Fremgangsmåde ifølge krav 19, hvor Z er brom.
21. Fremgangsmåde ifølge et hvilket som helst af kravene 18 til 20, hvor det rå escitalopram underkastes indledende oprensning, før escitalopramhydrobromidet udfældes i krystallinsk form.
22. Fremgangsmåde ifølge et hvilket som helst af kravene 18 til 21, kendetegnet ved, at escitalopram fri base omdannes til escitalopram-oxalat.
23. Fremgangsmåde til reduktion af mængden af escitalopram, W-oxid i escitalopram fri base eller et salt deraf, hvilken fremgangsmåde omfatter opløsning af escitalopram fri base i diethylether og fjernelse af escitalopram, W-oxid som et fast materiale.
24. Smeltetablet, der har en hårdhed på mindst 22 N og en oral desintegrationstid på mindre end 120 s, og som omfatter en aktiv farmaceutisk bestanddel adsorberet på et vandopløseligt fyldstof, ét eller flere desintegrationsmidler og eventuelt yderligere vandopløseligt fyldstof, hvor den aktive farmaceutiske bestanddel har et smeltepunkt i området 40-100 °C.
25. Smeltetablet ifølge krav 23, kendetegnet ved, at den aktive farmaceutiske bestanddel har et smeltepunkt i området 40-90 °C.
26. Smeltetablet ifølge krav 23 eller 24, kendetegnet ved, at den aktive farmaceutiske bestanddel er valgt fra gruppen bestående af escitalopram, ethosuximid, trimethadion, chlorambucil, disulfiram, fenofibrat, guaifenesin, lomustin, carisoprodol og perphenazin.
27. Smeltetablet ifølge krav 25, kendetegnet ved, at den aktive farmaceutiske bestanddel er escitalopram.
28. Smeltetablet ifølge et hvilket som helst af kravene 23-26, kendetegnet ved, at det vandopløselige fyldstof er valgt fra gruppen bestående af monosaccharider, disaccharider, sukkeralkoholer og polysaccharider.
29. Smeltetablet ifølge krav 27, k e n d e t e g n e t ved, at det vandopløselige fyldstof er valgt fra gruppen bestående af mannitol, sorbitol, glucose, mannose og lactose.
30. Smeltetablet ifølge et hvilket som helst af kravene 23-28, kendetegnet ved, at den har en hårdhed på mindst 22 N.
31. Smeltetablet ifølge et hvilket som helst af kravene 23-29, kendetegnet ved, at den har en oral desintegrationstid på mindre end 60 s.
32. Smeltetablet ifølge et hvilket som helst af kravene 23-30, kendetegnet ved, at desintegrationsmidlerne er valgt fra gruppen bestående af mikrokrystallinsk cellulose, natriumstivelsesglycolat, croscarmellose-natrium, crospovidon og povidon.
33. Smeltetablet ifølge et hvilket som helst af kravene 23-31, kendetegnet ved, at den har en slidstyrke på ikke mere end 1 %.
34. Fremgangsmåde til fremstilling af en smeltetablet ifølge et hvilket som helst af kravene 23-32, der omfatter; a) blanding af det vandopløselige fyldstof og den aktive farmaceutiske bestanddel ved en temperatur over, omkring eller lidt under den aktive farmaceutiske bestanddels smeltepunkt, hvorved den aktive farmaceutiske bestanddel adsorberes på det vandopløselige fyldstof; b) efterfulgt af afkøling til en temperatur under 40 °C; c) blanding af blandingen af den aktive farmaceutiske bestanddel og det vandopløselige fyldstof med ét eller flere desintegrationsmidler og eventuelt andre hjælpestoffer og d) presning af blandingen til tabletter med en hårdhed på mindst 22 N.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK200800075A DK200800075A (da) | 2005-06-22 | 2008-01-21 | Krystallinsk base af escitalopram og orodispergerbare tabletter indeholdende escitaloprambase |
DKPA200900284A DK200900284A (da) | 2005-06-22 | 2009-02-27 | Krystallinsk base af escitalopram og smeltetabletter indeholdende escitalopram base |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200500912 | 2005-06-22 | ||
DK200500912 | 2005-06-22 | ||
DK200800075 | 2008-01-21 | ||
DK200800075A DK200800075A (da) | 2005-06-22 | 2008-01-21 | Krystallinsk base af escitalopram og orodispergerbare tabletter indeholdende escitaloprambase |
Publications (1)
Publication Number | Publication Date |
---|---|
DK200800075A true DK200800075A (da) | 2008-03-15 |
Family
ID=37546630
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06742481.2T DK1896439T4 (da) | 2005-06-22 | 2006-06-22 | Krystallinsk base af escitalopram og orodispergerbare tabletter, der omfatter escitaloprambase |
DK200800075A DK200800075A (da) | 2005-06-22 | 2008-01-21 | Krystallinsk base af escitalopram og orodispergerbare tabletter indeholdende escitaloprambase |
DKPA200900284A DK200900284A (da) | 2005-06-22 | 2009-02-27 | Krystallinsk base af escitalopram og smeltetabletter indeholdende escitalopram base |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06742481.2T DK1896439T4 (da) | 2005-06-22 | 2006-06-22 | Krystallinsk base af escitalopram og orodispergerbare tabletter, der omfatter escitaloprambase |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DKPA200900284A DK200900284A (da) | 2005-06-22 | 2009-02-27 | Krystallinsk base af escitalopram og smeltetabletter indeholdende escitalopram base |
Country Status (39)
Country | Link |
---|---|
EP (3) | EP2325177A1 (da) |
JP (5) | JP4906852B2 (da) |
KR (5) | KR20110084341A (da) |
CN (2) | CN101189220A (da) |
AR (2) | AR055062A1 (da) |
AT (3) | AT10983U1 (da) |
AU (2) | AU2006261452B2 (da) |
BG (1) | BG66086B1 (da) |
BR (1) | BRPI0612295A2 (da) |
CA (2) | CA2646780A1 (da) |
CY (1) | CY1112392T1 (da) |
CZ (3) | CZ299906B6 (da) |
DE (2) | DE112006001619T5 (da) |
DK (3) | DK1896439T4 (da) |
EA (2) | EA201001108A1 (da) |
EE (1) | EE00773U1 (da) |
ES (2) | ES2356838T5 (da) |
FI (2) | FI20077133A (da) |
GB (2) | GB2442160B (da) |
HR (1) | HRP20110093T4 (da) |
HU (1) | HUP0800135A3 (da) |
IL (1) | IL187454A0 (da) |
IS (1) | IS8705A (da) |
LT (1) | LT5550B (da) |
LV (1) | LV13677B (da) |
MX (1) | MX2007015328A (da) |
MY (2) | MY143239A (da) |
NO (2) | NO20080359L (da) |
PL (2) | PL1896439T5 (da) |
PT (1) | PT1896439E (da) |
RS (1) | RS51575B2 (da) |
SG (1) | SG169358A1 (da) |
SI (1) | SI1896439T2 (da) |
SK (1) | SK500402007A3 (da) |
TR (2) | TR200708792T1 (da) |
TW (2) | TWI347942B (da) |
UA (1) | UA86536C2 (da) |
WO (1) | WO2006136169A2 (da) |
ZA (2) | ZA200711066B (da) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
WO2008059514A2 (en) * | 2006-07-31 | 2008-05-22 | Cadila Healthcare Limited | Process for preparing escitalopram |
EP2134325A2 (en) * | 2007-03-01 | 2009-12-23 | Aurobindo Pharma Limited | Stable solid dosage forms of an antidepressant |
ME02391B (me) | 2010-07-23 | 2016-09-20 | H Lundbeck As | Postupak za prečišćavanje farmaceutski prihvatljivih soli escitaloprama |
CN103360353A (zh) * | 2013-08-07 | 2013-10-23 | 中国药科大学 | 草酸艾司西酞普兰杂质的制备方法 |
JP2018016569A (ja) * | 2016-07-26 | 2018-02-01 | 株式会社トクヤマ | (1s)−1−[3−(ジメチルアミノ)プロピル]−1−(4−フルオロフェニル)−1,3−ジヒドロイソベンゾフラン−5−カルボニトリル蓚酸塩の製造方法 |
WO2018190294A1 (ja) * | 2017-04-10 | 2018-10-18 | 東和薬品株式会社 | エスシタロプラム医薬組成物 |
CN110711198B (zh) * | 2018-07-12 | 2022-03-15 | 山东大学 | D-甘露糖在制备抗抑郁药物中的应用 |
KR102331187B1 (ko) | 2019-04-09 | 2021-11-26 | 주식회사 라이트팜텍 | 에스시탈로프람을 함유하는 안정성이 우수한 경구용 액제 조성물 및 그의 제조방법 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1526331A (en) | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
GB8814057D0 (en) | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
JPH05222041A (ja) * | 1992-02-13 | 1993-08-31 | Mitsubishi Gas Chem Co Inc | アデニン誘導体の精製法 |
RU2161954C2 (ru) * | 1994-01-27 | 2001-01-20 | Дзе Борд оф Регентс оф Дзе Юниверсити оф Оклахома | Быстрорастворяющиеся во рту лекарственные формы |
US5607697A (en) * | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
AU4655597A (en) | 1997-06-30 | 1999-01-19 | Beloit Technologies, Inc. | Method and apparatus for the high speed application of coating to a traveling paper web |
DE69801764T2 (de) | 1997-07-08 | 2002-07-04 | Lundbeck & Co As H | Verfahren zur herstellung von citalopram |
DE69714480T2 (de) | 1997-11-11 | 2003-03-06 | Lundbeck & Co As H | Verfahren zur Herstellung von Citalopram |
FR2785538B1 (fr) * | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | Comprime a delitement rapide perfectionne |
US20020071864A1 (en) * | 1999-03-25 | 2002-06-13 | Yuhan Corporation | Rapidly disintegrable tablet for oral administration |
ITMI991581A1 (it) | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | Metodo per la preparazione di citalopram |
ITMI991579A1 (it) | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | Metodo per la preparazione di citalopram |
JP2001226372A (ja) * | 1999-12-06 | 2001-08-21 | Sumika Fine Chemicals Co Ltd | ロサルタンの結晶性または結晶化された酸付加塩およびロサルタンの精製方法 |
GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
US7510728B2 (en) * | 2000-10-06 | 2009-03-31 | Takeda Pharmaceutical Company Limited | Solid preparations |
JP4446463B2 (ja) * | 2000-10-16 | 2010-04-07 | 第一三共株式会社 | 口腔内速崩壊性医薬組成物およびその製造方法 |
US7799342B2 (en) | 2000-12-06 | 2010-09-21 | Wyeth Llc | Fast dissolving tablet |
TR200201166T1 (tr) * | 2000-12-22 | 2002-10-21 | H.Lundbecks A/S | Saf sitalopram hazırlanması için yöntem |
TR200200018T1 (tr) * | 2000-12-28 | 2002-06-21 | H. Lundbeck A/S | Saf sitalopram hazırlanması için yöntem. |
CA2445843A1 (en) * | 2001-05-01 | 2002-11-07 | H. Lundbeck A/S | The use of enantiomeric pure escitalopram |
US6872405B2 (en) * | 2001-05-10 | 2005-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Quick-disintegrating tablet in buccal cavity and manufacturing method thereof |
GB0113842D0 (en) * | 2001-06-07 | 2001-08-01 | Boots Co Plc | Therapeutic agents |
AR034612A1 (es) * | 2001-06-25 | 2004-03-03 | Lundbeck & Co As H | Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram |
AR034759A1 (es) | 2001-07-13 | 2004-03-17 | Lundbeck & Co As H | Metodo para la preparacion de escitalopram |
TR200400189T2 (tr) * | 2001-07-31 | 2004-12-21 | H.Lundbeck A/S | Esitalopram içeren kristal yapılı bileşim. |
IS7239A (is) | 2001-12-14 | 2004-04-29 | H. Lundbeck A/S | Aðferð til framleiðslu á essítalóprami |
US7148364B2 (en) * | 2002-01-07 | 2006-12-12 | Sun Pharmaceutical Industries | Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile |
FR2834889B1 (fr) * | 2002-01-18 | 2004-04-02 | Roquette Freres | Forme pharmaceutique solide orodispersible |
GB0204607D0 (en) * | 2002-02-27 | 2002-04-10 | Matrix Lab Ltd | Process |
EP2228060A1 (en) * | 2002-05-03 | 2010-09-15 | Skyepharma Canada Inc. | Oral dosage forms comprising fenofibrate |
CN100349885C (zh) | 2002-12-23 | 2007-11-21 | H·隆德贝克有限公司 | 依他普仑氢溴酸盐及其制备方法 |
CN1510024A (zh) * | 2002-12-24 | 2004-07-07 | 北京德众万全药物技术开发有限公司 | 可用于制备西酞普兰(s)-对映异构体的新的化合物及其制备方法 |
DE10305984A1 (de) * | 2003-02-13 | 2004-09-02 | Helm Ag | Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen |
AU2004238321B2 (en) * | 2003-05-07 | 2009-08-27 | Samyang Biopharmaceuticals Corporation | Highly plastic granules for making fast melting tablets |
IN234086B (da) * | 2003-10-15 | 2009-05-29 | Fuji Chem Ind Co Ltd | |
WO2005049596A1 (en) * | 2003-11-20 | 2005-06-02 | Natco Pharma Limited | A process for the preparation of high purity escitalopram |
HU227491B1 (en) * | 2003-11-25 | 2011-07-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Tablet containing citalopram hydrogen bromide |
EA200601641A1 (ru) * | 2004-03-05 | 2006-12-29 | Х. Лундбекк А/С | Кристаллическая композиция, содержащая оксалат эсциталопрама |
WO2006106531A1 (en) * | 2005-04-04 | 2006-10-12 | Jubilant Organosys Ltd | Process for the preparation of escitalopram or its acid addition salts |
-
2006
- 2006-06-15 TW TW095121358A patent/TWI347942B/zh not_active IP Right Cessation
- 2006-06-15 TW TW100102601A patent/TWI358407B/zh not_active IP Right Cessation
- 2006-06-21 MY MYPI2010000618A patent/MY143239A/en unknown
- 2006-06-21 AR ARP060102654A patent/AR055062A1/es not_active Application Discontinuation
- 2006-06-21 MY MYPI20062933A patent/MY143252A/en unknown
- 2006-06-22 SI SI200630923T patent/SI1896439T2/sl unknown
- 2006-06-22 CA CA002646780A patent/CA2646780A1/en not_active Abandoned
- 2006-06-22 EP EP10179395A patent/EP2325177A1/en not_active Withdrawn
- 2006-06-22 EA EA201001108A patent/EA201001108A1/ru unknown
- 2006-06-22 SK SK50040-2007A patent/SK500402007A3/sk unknown
- 2006-06-22 KR KR1020117015711A patent/KR20110084341A/ko not_active Application Discontinuation
- 2006-06-22 ES ES06742481.2T patent/ES2356838T5/es active Active
- 2006-06-22 GB GB0724557A patent/GB2442160B/en not_active Expired - Fee Related
- 2006-06-22 CZ CZ20070898A patent/CZ299906B6/cs not_active IP Right Cessation
- 2006-06-22 ES ES200750085A patent/ES2319073B1/es not_active Expired - Fee Related
- 2006-06-22 CN CNA2006800200393A patent/CN101189220A/zh active Pending
- 2006-06-22 CZ CZ20080429A patent/CZ301286B6/cs not_active IP Right Cessation
- 2006-06-22 WO PCT/DK2006/000366 patent/WO2006136169A2/en active Application Filing
- 2006-06-22 HU HU0800135A patent/HUP0800135A3/hu unknown
- 2006-06-22 RS RS20110057A patent/RS51575B2/sr unknown
- 2006-06-22 DK DK06742481.2T patent/DK1896439T4/da active
- 2006-06-22 EP EP06742481.2A patent/EP1896439B2/en active Active
- 2006-06-22 KR KR1020077028918A patent/KR20080018191A/ko not_active Application Discontinuation
- 2006-06-22 AT AT0900506U patent/AT10983U1/de not_active IP Right Cessation
- 2006-06-22 KR KR1020127014205A patent/KR20120064140A/ko not_active Application Discontinuation
- 2006-06-22 BR BRPI0612295-7A patent/BRPI0612295A2/pt not_active IP Right Cessation
- 2006-06-22 TR TR2007/08792T patent/TR200708792T1/xx unknown
- 2006-06-22 SG SG201100648-3A patent/SG169358A1/en unknown
- 2006-06-22 PL PL06742481T patent/PL1896439T5/pl unknown
- 2006-06-22 CN CN201010286088XA patent/CN101928269A/zh active Pending
- 2006-06-22 PL PL384185A patent/PL384185A1/pl unknown
- 2006-06-22 CZ CZ20080430A patent/CZ300686B6/cs not_active IP Right Cessation
- 2006-06-22 KR KR1020117005777A patent/KR101340815B1/ko active IP Right Grant
- 2006-06-22 KR KR1020107026804A patent/KR20100133023A/ko not_active Application Discontinuation
- 2006-06-22 AU AU2006261452A patent/AU2006261452B2/en not_active Withdrawn - After Issue
- 2006-06-22 DE DE112006001619T patent/DE112006001619T5/de not_active Withdrawn
- 2006-06-22 PT PT06742481T patent/PT1896439E/pt unknown
- 2006-06-22 DE DE602006019961T patent/DE602006019961D1/de active Active
- 2006-06-22 AT AT06742481T patent/ATE497500T1/de active
- 2006-06-22 TR TR2010/00625T patent/TR201000625T1/xx unknown
- 2006-06-22 GB GB0811164A patent/GB2448834B/en not_active Expired - Fee Related
- 2006-06-22 ZA ZA200711066A patent/ZA200711066B/xx unknown
- 2006-06-22 EP EP10179318A patent/EP2385044A1/en not_active Withdrawn
- 2006-06-22 EA EA200800102A patent/EA019239B1/ru not_active IP Right Cessation
- 2006-06-22 UA UAA200800362A patent/UA86536C2/ru unknown
- 2006-06-22 CA CA2612827A patent/CA2612827C/en not_active Expired - Fee Related
- 2006-06-22 EE EEU200800003U patent/EE00773U1/xx not_active IP Right Cessation
- 2006-06-22 MX MX2007015328A patent/MX2007015328A/es active IP Right Grant
- 2006-06-22 JP JP2008517323A patent/JP4906852B2/ja active Active
-
2007
- 2007-11-18 IL IL187454A patent/IL187454A0/en unknown
- 2007-12-19 BG BG10110024A patent/BG66086B1/bg unknown
- 2007-12-20 FI FI20077133A patent/FI20077133A/fi unknown
- 2007-12-21 LV LVP-07-157A patent/LV13677B/lv unknown
-
2008
- 2008-01-14 IS IS8705A patent/IS8705A/is unknown
- 2008-01-18 NO NO20080359A patent/NO20080359L/no unknown
- 2008-01-21 DK DK200800075A patent/DK200800075A/da not_active Application Discontinuation
- 2008-01-21 LT LT2008005A patent/LT5550B/lt not_active IP Right Cessation
- 2008-10-07 JP JP2008260742A patent/JP4415056B2/ja active Active
- 2008-10-07 FI FI20080548A patent/FI20080548A/fi unknown
-
2009
- 2009-02-27 DK DKPA200900284A patent/DK200900284A/da not_active Application Discontinuation
- 2009-03-10 ZA ZA200901698A patent/ZA200901698B/en unknown
- 2009-05-12 JP JP2009115279A patent/JP2009179634A/ja active Pending
- 2009-05-12 JP JP2009115280A patent/JP2009179635A/ja active Pending
- 2009-07-07 AT AT0041709U patent/AT11883U1/de not_active IP Right Cessation
-
2010
- 2010-03-05 AU AU2010200844A patent/AU2010200844A1/en not_active Withdrawn
- 2010-12-20 NO NO20101777A patent/NO20101777L/no not_active Application Discontinuation
- 2010-12-27 AR ARP100104958A patent/AR079750A2/es not_active Application Discontinuation
-
2011
- 2011-02-03 CY CY20111100116T patent/CY1112392T1/el unknown
- 2011-02-04 HR HRP20110093TT patent/HRP20110093T4/hr unknown
- 2011-11-24 JP JP2011255804A patent/JP5731957B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK200800075A (da) | Krystallinsk base af escitalopram og orodispergerbare tabletter indeholdende escitaloprambase | |
Robinson | CCXXXII.—A new synthesis of oxazole derivatives | |
TWI799115B (zh) | 2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)苯甲醛之游離鹼的結晶多晶型物 | |
US9856270B2 (en) | Dolutegravir salts | |
JP2013516473A5 (da) | ||
JP2024063140A (ja) | トホグリフロジンを含有する固形製剤及びその製造方法 | |
WO2016131431A1 (en) | Solid forms of empagliflozin | |
KR20060080817A (ko) | 시부트라민의 디카복실산염 | |
US10538506B2 (en) | Crystal form of a potassium-competitive acid blocker and preparation method thereof | |
RU2290924C2 (ru) | Фармацевтическая композиция, включающая кристаллический полугидрат метансульфоната сибутрамина | |
BE1013559A6 (fr) | Composition pharmaceutique contenant du citalopram. | |
CN102260244B (zh) | 一种稳定的雷贝拉唑钠化合物 | |
TW200900392A (en) | Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same | |
NO119949B (da) | ||
RU2013157528A (ru) | Покрытая сухим способом таблетка, содержащая тегафур, гимерацил и отерацил калия | |
RU2012121183A (ru) | Фармацевтическая композиция для перорального введения | |
JP4740875B2 (ja) | アムロジピンのゲンチシン酸塩及びその製造方法 | |
MXPA03005886A (es) | Derivado de aspartato de amlodipina como antagonista del canal de calcio. | |
RU2019106531A (ru) | Кристалл соли производного хиназолина | |
CN106946828A (zh) | 东莨菪内酯酚醚衍生物及其制备方法和应用 | |
BG106112A (bg) | Ново фармацевтично средство | |
CN103242291A (zh) | 一种多晶型高含量苯甲酸阿格列汀的批量生产工艺 | |
JP2014526480A (ja) | 塩酸イダルビシンの結晶化 | |
KR101896062B1 (ko) | 무정형 리나글립틴의 제조 방법 | |
JPH06116146A (ja) | 製 剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ATS | Application withdrawn |